•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.ADT: Recurring Customer Base Is Still Weak
All You Need to Know About ADT (ADT) Rating Upgrade to Buy
Are Investors Undervaluing ADT (ADT) Right Now?
ADT Helps Bring Communities Together for National Night Out 2026
First Trust Advisors LP Grows Stake in ADT Inc. $ADT
ADT Inc. (ADT) Q2 2026 Earnings Call Transcript
ADT (ADT) Tops Q2 Earnings and Revenue Estimates
ADT Reports Second Quarter 2026 Results
4 Security and Safety Stocks to Watch Despite Industry Headwinds
ADT to Release Second Quarter 2026 Results on Thursday, July 30th
ADT Earns Two 2026 Buyer's Choice Awards from ConsumerAffairs, Based on Customer Reviews
ADT Joins Board of Directors of the Connectivity Standards Alliance, Reinforcing Its Role in Shaping the Future of the Connected Home
Should Value Investors Buy ADT (ADT) Stock?
Buy 2 Ideal June DiviDogs Per Barron's April To June Picks
Are Investors Undervaluing ADT (ADT) Right Now?
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
ADT (ADT) Upgraded to Buy: Here's Why
ADT Announces Yet Another DIY Home Security Line, Now With AI Features
ADT Has A Clear AI-Driven Future (Rating Upgrade)
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer